trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Ventricular Remodeling D020257 28 associated lipids
Endometriosis D004715 29 associated lipids
Adrenoleukodystrophy D000326 29 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Cardiomegaly D006332 31 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Osteosarcoma D012516 50 associated lipids
Asthma D001249 52 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Nerve Degeneration D009410 53 associated lipids
Reperfusion Injury D015427 65 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Neuroblastoma D009447 66 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Leukemia D007938 74 associated lipids
Alzheimer Disease D000544 76 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Glioma D005910 112 associated lipids
Hypertension D006973 115 associated lipids
Inflammation D007249 119 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Mizutani H et al. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide. 2010 Cancer Sci. pmid:20624163
Sakuma M et al. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. 2007 Cancer Sci. pmid:17270028
Hattori N et al. Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. 2011 Cancer Sci. pmid:21489049
Furumai R et al. Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment. 2011 Cancer Sci. pmid:21299717
Yamada Y et al. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer. 2003 Cancer Sci. pmid:12824880
Yang X et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. 2001 Cancer Res. pmid:11585728
Luo W et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. 2010 Cancer Res. pmid:20587525
Sasaki Y et al. p53 negatively regulates the hepatoma growth factor HDGF. 2011 Cancer Res. pmid:22006999
Phan D et al. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. 2004 Cancer Res. pmid:15126343
Wang X et al. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. 2009 Cancer Res. pmid:19752087
Wei M et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. 2005 Cancer Res. pmid:16322213
Hatjiharissi E et al. Proteomic analysis of waldenstrom macroglobulinemia. 2007 Cancer Res. pmid:17440091
Mariadason JM et al. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. 2000 Cancer Res. pmid:10969808
Hellebrekers DM et al. Identification of epigenetically silenced genes in tumor endothelial cells. 2007 Cancer Res. pmid:17483324
James SY et al. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. 2003 Cancer Res. pmid:12839938
Fahrner JA et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. 2002 Cancer Res. pmid:12499261
Terui T et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. 2003 Cancer Res. pmid:14695212
Lau QC et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. 2006 Cancer Res. pmid:16818622
Su Y et al. Human RecQL4 helicase plays critical roles in prostate carcinogenesis. 2010 Cancer Res. pmid:21045146
Sugita K et al. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. 1992 Cancer Res. pmid:1727377
Qi H and Ratnam M Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. 2006 Cancer Res. pmid:16740727
Ibanez de Caceres I et al. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. 2006 Cancer Res. pmid:16707423
Imre G et al. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. 2006 Cancer Res. pmid:16707469
Singal R et al. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. 2001 Cancer Res. pmid:11406558
Maecker HL et al. p53 promotes selection for Fas-mediated apoptotic resistance. 2000 Cancer Res. pmid:10969818
Badia E et al. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. 2000 Cancer Res. pmid:10945620
Blagosklonny MV et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. 2005 Cancer Res. pmid:16103091
Sirchia SM et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. 2002 Cancer Res. pmid:11980632
Shin JY et al. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. 2000 Cancer Res. pmid:10667572
Kretzner L et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. 2011 Cancer Res. pmid:21502403
Saunders N et al. Histone deacetylase inhibitors as potential anti-skin cancer agents. 1999 Cancer Res. pmid:9927053
Ramsey MR et al. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. 2011 Cancer Res. pmid:21527555
Harada K et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. 2002 Cancer Res. pmid:12384554
Wilson AJ et al. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. 2002 Cancer Res. pmid:12414619
Ho WC et al. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. 2005 Cancer Res. pmid:15899819
Tran T et al. Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. 2005 Cancer Res. pmid:15899836
Kim MS et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. 2003 Cancer Res. pmid:14612526
Majid S et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. 2010 Cancer Res. pmid:20332239
Liu LT et al. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. 2003 Cancer Res. pmid:12810630
Sowa Y et al. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. 1999 Cancer Res. pmid:10485470
Myzak MC et al. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. 2004 Cancer Res. pmid:15313918
Kim TY et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. 2006 Cancer Res. pmid:16885346
Xiong Y et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. 2005 Cancer Res. pmid:15805266
Ferrara FF et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. 2001 Cancer Res. pmid:11196162
Kumakura S et al. Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. 2005 Cancer Res. pmid:15805278
Zhao S et al. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. 2003 Cancer Res. pmid:12750289
Yang X et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. 2000 Cancer Res. pmid:11156387
Nervi C et al. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. 2001 Cancer Res. pmid:11245412
Zhu WG et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. 2001 Cancer Res. pmid:11245429
Pellicciotta I et al. Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. 2008 Cancer Res. pmid:18829567